semaglutide cardiovascular outcomes news Weight loss and disease risk of semaglutide: a one-year multicentered study Semaglutide and Cardiovascular Outcomes in

Read more in the full press release: Everyones talking about GLP-1s

While the established side effect profile of Mounjaro is well documented through clinical trials and post-marketing surveillance, some patients have raised concerns about experiencing restless legs or unusual leg sensations whilst taking the medication, prompting questions about whether there is a direct link

Furthermore, co-treatment with a GLP-1R agonist and a GIPR agonist results in more insulin sensitivity, glucose reduction, food intake reduction, and body weight reduction than either agonist alone in obese mice with type 2 diabetes (33)

This can be a good thing, especially if youre taking the drug to manage your type 2 diabetes